← All trials
NCT01511419
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2012
- Primary completion
- Jun 1, 2012
- Completion date
- Jul 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- PATHLead sponsor
- Microgen Scientific Industrial Company for Immunobiological MedicinesCollaborator
- PATHStudy director
- Microgen Scientific Industrial Company for Immunobiological MedicinesStudy director
- Research Institute of Influenza, RussiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.